- The company recorded DKK 6.3 billion in non-cash impairment charges on development assets.
- Monlunabant accounted for DKK 4.0 billion of the charge.
- Novo raised its full-year adjusted sales and operating profit outlook, while still allowing for a decline of up to 6 per cent at constant exchange rates.
Inside this story 2 perspectives
Two statements in Novo Nordisk’s 4 August results describe different kinds of confidence. The Danish drugmaker improved its expectations for full-year sales and operating profit on an adjusted basis. It also reduced the value it places on intangible assets in its development pipeline by 6.3 billion Danish kroner. A company can make both decisions together because the medicines generating revenue today and the projects intended to generate it tomorrow face different tests.
Monlunabant accounted for 4.0 billion kroner of the impairment charges announced for the second quarter. The charge was non-cash. It reduced reported earnings without requiring the company to pay out 4.0 billion kroner for that project during the quarter. The money and work associated with developing an asset can belong to earlier periods. The carrying value in the accounts reflects a judgment about the future benefits that work will bring.
What a write-down tells the board
Research-based companies commit resources before they know which projects will have a market. An accounting charge records a change in the value of an asset already on the books. It does not by itself disclose every scientific result or specify every decision about further research. It does tell the board and shareholders that the company no longer expects the recorded value to be fully recoverable under its assessment.
That distinction had an unusually large effect on the quarter’s headline. Reported operating profit fell 16 per cent at constant exchange rates. Adjusted operating profit rose 11 per cent on the same currency basis to approximately 33.4 billion kroner. The adjustment removes the pipeline impairments and accounts for specified effects related to US drug-pricing rebate provisions. The comparative quarter a year earlier had included a reversal of a rebate provision. An observer looking at the two profit growth rates is therefore seeing the effects of more than one accounting event.
The commercial test for a new medicine
At the same time, Novo raised its full-year outlook for adjusted sales and operating profit at constant exchange rates. Its new range for each ran from a decline of 6 per cent to no change on the prior year. A better forecast can still include falling sales. The change is in the expected range of outcomes, measured against the previous forecast.
Reuters reported that sales of the Wegovy pill reached 3.22 billion kroner, just below the 3.3 billion expected by analysts in its report. That offers another example of how a board and a market can look at the same business and ask different questions. The board has to decide which future projects justify continued resources. Investors also compare the commercial performance of products already on sale with the expectations built into their valuations. This quarter placed the cost of changing one expectation beside the consequences of narrowly missing another.



